Bank Albilad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Bank Albilad heeft totale activa van SAR153.7B en een totaal eigen vermogen van SAR16.1B. De totale deposito's bedragen SAR126.5B, en de totale leningen bedragen SAR106.7B.

Belangrijke informatie

9.5x

Verhouding activa / eigen vermogen

n/a

Nettorentemarge

Totaal deposito's	ر.س126.45b
Verhouding leningen/deposito's	Passend
Slechte leningen	1.2%
Voorziening voor dubieuze leningen	Voldoende
Huidige ratio	Laag
Geldmiddelen en kasequivalenten	ر.س13.22b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Here's Why We Think Bank Albilad (TADAWUL:1140) Might Deserve Your Attention Today

Sep 20

Here's Why We Think Bank Albilad (TADAWUL:1140) Might Deserve Your Attention Today

May 31

Here's Why We Think Bank Albilad (TADAWUL:1140) Is Well Worth Watching

Feb 05

Bank Albilad (TADAWUL:1140) Ticks All The Boxes When It Comes To Earnings Growth

Oct 23

Here's Why We Think Bank Albilad (TADAWUL:1140) Is Well Worth Watching

Jul 07

If EPS Growth Is Important To You, Bank Albilad (TADAWUL:1140) Presents An Opportunity

Mar 22

Investors Who Bought Bank Albilad (TADAWUL:1140) Shares Five Years Ago Are Now Up 87%

Feb 14

What Type Of Shareholders Own The Most Number of Bank Albilad (TADAWUL:1140) Shares?

Jan 18

What Makes Bank Albilad (TADAWUL:1140) A Great Dividend Stock?

Dec 23

Do Bank Albilad's (TADAWUL:1140) Earnings Warrant Your Attention?

Nov 27

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse financiële instellingen

Activa niveau: De Vermogen/vermogensverhouding ( 9.5 x) 1140 is laag.

Voorziening voor slechte leningen: 1140 heeft een voldoende voorziening voor slechte leningen ( 203 %).

Laag risico verplichtingen: 92% van de verplichtingen van 1140 bestaan voornamelijk uit laag risico financieringsbronnen.

Leenniveau: 1140 heeft een passend niveau van Leningen/activa-ratio ( 69% ).

Laag risico deposito's: De Leningen-depositoverhouding ( 84% ) van 1140 } is passend.

Niveau van slechte leningen: 1140 heeft een passend niveau van slechte leningen ( 1.2 %).

Bank Albilad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Third quarter 2024 earnings released: EPS: ر.س0.57 (vs ر.س0.50 in 3Q 2023)

New minor risk - Dividend sustainability

Here's Why We Think Bank Albilad (TADAWUL:1140) Might Deserve Your Attention Today

Second quarter 2024 earnings released: EPS: ر.س0.54 (vs ر.س0.47 in 2Q 2023)

Here's Why We Think Bank Albilad (TADAWUL:1140) Might Deserve Your Attention Today

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings released: EPS: ر.س2.38 (vs ر.س2.09 in FY 2022)

Bank Albilad Recommends to Distribute Cash Dividends for 2023

Here's Why We Think Bank Albilad (TADAWUL:1140) Is Well Worth Watching

Bank Albilad (TADAWUL:1140) Ticks All The Boxes When It Comes To Earnings Growth

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 8.7% to ر.س38.38

Here's Why We Think Bank Albilad (TADAWUL:1140) Is Well Worth Watching

Consensus EPS estimates fall by 15%

First quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of ر.س0.50 per share at 1.2% yield

If EPS Growth Is Important To You, Bank Albilad (TADAWUL:1140) Presents An Opportunity

Full year 2022 earnings: EPS misses analyst expectations

Bank Albilad Recommends Cash Dividends for the Year 2022

Do Bank Albilad's (TADAWUL:1140) Earnings Warrant Your Attention?

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Do Bank Albilad's (TADAWUL:1140) Earnings Warrant Your Attention?

Second quarter 2022 earnings released: EPS: ر.س0.51 (vs ر.س0.42 in 2Q 2021)

Price target increased to ر.س36.95

Here's Why We Think Bank Albilad (TADAWUL:1140) Is Well Worth Watching

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Bank Albilad Announces Executive Changes

Bank Albilad Announces Resignation of Khalid Abdulaziz Almukairin as Board of Directors, with Effect from April 17, 2022

Full year 2021 earnings: EPS misses analyst expectations

Here's Why I Think Bank Albilad (TADAWUL:1140) Is An Interesting Stock

Third quarter 2021 earnings released

Does Bank Albilad (TADAWUL:1140) Deserve A Spot On Your Watchlist?

Price target increased to ر.س38.76

Price target increased to ر.س34.80

Second quarter 2021 earnings released

Here's Why I Think Bank Albilad (TADAWUL:1140) Is An Interesting Stock

First quarter 2021 earnings released: EPS ر.س0.53 (vs ر.س0.36 in 1Q 2020)

Price target increased to ر.س28.98

How Does Bank Albilad (TADAWUL:1140) Fare As A Dividend Stock?

Consensus EPS estimates increase to ر.س2.10

Price target increased to ر.س26.91

Here's Why I Think Bank Albilad (TADAWUL:1140) Is An Interesting Stock

Investors Who Bought Bank Albilad (TADAWUL:1140) Shares Five Years Ago Are Now Up 87%

Full year 2020 earnings released: EPS ر.س1.81 (vs ر.س1.67 in FY 2019)

Revenue and earnings beat expectations

New 90-day high: ر.س29.00

Bank Albilad Announces Management Changes

Bank Albilad Announces Demise of the Chairman of the Board of Directors Abdulrahman Bin Ibrahim Al Humid

What Type Of Shareholders Own The Most Number of Bank Albilad (TADAWUL:1140) Shares?

New 90-day high: ر.س28.85

What Makes Bank Albilad (TADAWUL:1140) A Great Dividend Stock?

New 90-day high: ر.س28.00

Analysts update estimates

Do Bank Albilad's (TADAWUL:1140) Earnings Warrant Your Attention?

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS ر.س0.51

Revenue and earnings beat expectations

Third quarter earnings released

New 90-day low: ر.س23.26

Price target raised to ر.س24.47

New 90-day high - ر.س25.50

First half earnings released

New 90-day high - ر.س24.16

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse financiële instellingen

Ontdek gezonde bedrijven